Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283399455> ?p ?o ?g. }
- W4283399455 endingPage "1342" @default.
- W4283399455 startingPage "1329" @default.
- W4283399455 abstract "Controlled infection studies in malaria-naive adults suggest increased vaccine efficacy for fractional-dose versus full-dose regimens of RTS,S/AS01. We report first results of an ongoing trial assessing different fractional-dose regimens in children, in natural exposure settings.This open-label, phase 2b, randomised controlled trial is conducted at the Malaria Research Center, Agogo, Ashanti Region (Ghana), and the Kenya Medical Research Institute and the US Centers for Disease Control and Prevention site in Siaya County (Kenya). We enrolled children aged 5-17 months without serious acute or chronic illness who had previously received three doses of diphtheria, tetanus, pertussis, and hepatitis B vaccine and at least three doses of oral polio vaccine. Children were randomly assigned (1:1:1:1:1) using a web-based randomisation system with a minimisation procedure accounting for centre to receive rabies control vaccine (M012 schedule) or two full doses of RTS,S/AS01E at month 0 and month 1, followed by either full doses at months 2 and 20 (group R012-20 [standard regimen]), full doses at months 2, 14, 26, and 38 (R012-14), fractional doses at months 2, 14, 26, and 38 (Fx012-14), or fractional doses at months 7, 20, and 32 (Fx017-20). The fractional doses were administered as one fifth (0·1 mL) of the full RTS,S dose (0·5 mL) after reconstitution. All vaccines were administered by intramuscular injection in the left deltoid. The primary outcome was occurrence of clinical malaria cases from month 2·5 until month 14 for the Fx012-14 group versus the pooled R012-14 and R012-20 groups in the per-protocol set. We assessed incremental vaccine efficacy of the Fx012-14 group versus the pooled R012-14 and R012-20 group over 12 months after dose three. Safety was assessed in all children who received at least one vaccine dose. This trial is registered with ClinicalTrials.gov, NCT03276962.Between Sept 28, 2017, and Sept 25, 2018, 2157 children were enrolled, of whom 1609 were randomly assigned to a treatment group (322 to each RTS,S/AS01E group and 321 to the rabies vaccine control group). 1500 children received at least one study vaccine dose and the per-protocol set comprised 1332 children. Over 12 months after dose three, the incremental vaccine efficacy in the Fx012-14 group versus the pooled R012-14 and R12-20 groups was -21% (95% CI -57 to 7; p=0·15). Up to month 21, serious adverse events occurred in 48 (16%) of 298 children in the R012-20 group, 45 (15%) of 294 in the R012-14 group, 47 (15%) of 304 in the Fx012-14 group, 62 (20%) of 311 in the Fx017-20 group, and 71 (24%) of 293 in the control group, with no safety signals observed.The Fx012-14 regimen was not superior to the standard regimen over 12 months after dose three. All RTS,S/AS01E regimens provided substantial, similar protection against clinical malaria, suggesting potential flexibility in the recommended dosing regimen and schedule. This, and the effect of annual boosters, will be further evaluated through 50 months of follow-up.GlaxoSmithKline Biologicals; PATH's Malaria Vaccine Initiative." @default.
- W4283399455 created "2022-06-25" @default.
- W4283399455 creator A5000942257 @default.
- W4283399455 creator A5002180546 @default.
- W4283399455 creator A5002406107 @default.
- W4283399455 creator A5003836097 @default.
- W4283399455 creator A5004272799 @default.
- W4283399455 creator A5004821105 @default.
- W4283399455 creator A5005978868 @default.
- W4283399455 creator A5006416160 @default.
- W4283399455 creator A5009874970 @default.
- W4283399455 creator A5011882174 @default.
- W4283399455 creator A5012894836 @default.
- W4283399455 creator A5015183702 @default.
- W4283399455 creator A5016750719 @default.
- W4283399455 creator A5019287160 @default.
- W4283399455 creator A5020421978 @default.
- W4283399455 creator A5020886187 @default.
- W4283399455 creator A5026480628 @default.
- W4283399455 creator A5027700663 @default.
- W4283399455 creator A5027767201 @default.
- W4283399455 creator A5030170744 @default.
- W4283399455 creator A5032686679 @default.
- W4283399455 creator A5041726477 @default.
- W4283399455 creator A5050318295 @default.
- W4283399455 creator A5051476386 @default.
- W4283399455 creator A5056689960 @default.
- W4283399455 creator A5057368704 @default.
- W4283399455 creator A5059139407 @default.
- W4283399455 creator A5059907819 @default.
- W4283399455 creator A5061266932 @default.
- W4283399455 creator A5064000965 @default.
- W4283399455 creator A5066884815 @default.
- W4283399455 creator A5066922340 @default.
- W4283399455 creator A5067238586 @default.
- W4283399455 creator A5071579540 @default.
- W4283399455 creator A5072697665 @default.
- W4283399455 creator A5077528263 @default.
- W4283399455 creator A5082738867 @default.
- W4283399455 creator A5083056084 @default.
- W4283399455 creator A5087318141 @default.
- W4283399455 creator A5089721938 @default.
- W4283399455 date "2022-09-01" @default.
- W4283399455 modified "2023-10-02" @default.
- W4283399455 title "Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial" @default.
- W4283399455 cites W1508120038 @default.
- W4283399455 cites W1994101226 @default.
- W4283399455 cites W2004574254 @default.
- W4283399455 cites W2046182783 @default.
- W4283399455 cites W2051074148 @default.
- W4283399455 cites W2057099099 @default.
- W4283399455 cites W2061493901 @default.
- W4283399455 cites W2108476551 @default.
- W4283399455 cites W2117914570 @default.
- W4283399455 cites W2136901678 @default.
- W4283399455 cites W2138692289 @default.
- W4283399455 cites W2340524139 @default.
- W4283399455 cites W2436449558 @default.
- W4283399455 cites W2744836284 @default.
- W4283399455 cites W2942029710 @default.
- W4283399455 cites W2946248791 @default.
- W4283399455 cites W2989310728 @default.
- W4283399455 cites W3019215984 @default.
- W4283399455 cites W3044633595 @default.
- W4283399455 cites W3203327071 @default.
- W4283399455 cites W4200303944 @default.
- W4283399455 cites W4205324914 @default.
- W4283399455 cites W4254848468 @default.
- W4283399455 cites W65828984 @default.
- W4283399455 doi "https://doi.org/10.1016/s1473-3099(22)00273-0" @default.
- W4283399455 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35753316" @default.
- W4283399455 hasPublicationYear "2022" @default.
- W4283399455 type Work @default.
- W4283399455 citedByCount "15" @default.
- W4283399455 countsByYear W42833994552021 @default.
- W4283399455 countsByYear W42833994552022 @default.
- W4283399455 countsByYear W42833994552023 @default.
- W4283399455 crossrefType "journal-article" @default.
- W4283399455 hasAuthorship W4283399455A5000942257 @default.
- W4283399455 hasAuthorship W4283399455A5002180546 @default.
- W4283399455 hasAuthorship W4283399455A5002406107 @default.
- W4283399455 hasAuthorship W4283399455A5003836097 @default.
- W4283399455 hasAuthorship W4283399455A5004272799 @default.
- W4283399455 hasAuthorship W4283399455A5004821105 @default.
- W4283399455 hasAuthorship W4283399455A5005978868 @default.
- W4283399455 hasAuthorship W4283399455A5006416160 @default.
- W4283399455 hasAuthorship W4283399455A5009874970 @default.
- W4283399455 hasAuthorship W4283399455A5011882174 @default.
- W4283399455 hasAuthorship W4283399455A5012894836 @default.
- W4283399455 hasAuthorship W4283399455A5015183702 @default.
- W4283399455 hasAuthorship W4283399455A5016750719 @default.
- W4283399455 hasAuthorship W4283399455A5019287160 @default.
- W4283399455 hasAuthorship W4283399455A5020421978 @default.
- W4283399455 hasAuthorship W4283399455A5020886187 @default.
- W4283399455 hasAuthorship W4283399455A5026480628 @default.
- W4283399455 hasAuthorship W4283399455A5027700663 @default.
- W4283399455 hasAuthorship W4283399455A5027767201 @default.
- W4283399455 hasAuthorship W4283399455A5030170744 @default.